According to recent reports released by Chroma Therapeutics and CTI, there is a new breakthrough in the management and treatment of AML (acute myelogenous leukemia), the fastest and commonest form of leukemia, with over 12,000 new cases reported each year in America alone.
The latest reports of the OPAL Phase 2 trial on Tosedostat, published in The Lancet Oncology, suggest that a once-daily Tosedostat dose can control the disease process up to 51%. The phase 2 trial was conducted in elderly subjects with a history of refractory or recurrent AML under Texas University researchers, Dr. Jorge Cortes. The trial results also suggested the maximum benefit of therapy is reported in patients who were otherwise refractory to conventional therapies, or those with symptoms of myelodysplatic syndrome. Clinical efficacy of Tosedostat is also reportedly better in patient who underwent prior hypomethylating therapy (HMA).
Tosedostat is an orally administered drug that acts as aminopeptidase inhibitor; (the mode of action is to deprive fast growing tumor blast cells from amino- acid building blocks). Both phase I and phase II trials indicates that Tosedostat is a well- tolerated drug because of selective amino-acid toxicity and manifest excelled long term prognosis and clinical efficacy with manageable and predictable side-effects.
AML is reported more frequently in elderly population with 5 year survival rate of 15 to 70% and relapse rate of 33 to 78%. Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. are hopeful that Tosedostat will prove helpful in the long term treatment and management of AML without affecting the systemic functioning of patients.